These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35003333)

  • 21. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know.
    Zelenetz AD
    J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1424-1426. PubMed ID: 31766021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres.
    Hester A; Gaß P; Fasching PA; Krämer AK; Ettl J; Diessner J; Wöckel A; Egger T; Stock K; Redlin J; Andraschko M; Harbeck N; Würstlein R
    Geburtshilfe Frauenheilkd; 2020 Sep; 80(9):924-931. PubMed ID: 32905322
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database.
    Nikitina V; Santi Laurini G; Montanaro N; Motola D
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
    Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
    JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
    Busse A; Lüftner D
    Breast Care (Basel); 2019 Mar; 14(1):10-16. PubMed ID: 31019437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
    Rosen LS; Jacobs IA; Burkes RL
    Target Oncol; 2017 Oct; 12(5):599-610. PubMed ID: 28801849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
    Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
    Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
    Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China.
    Wu Q; Lian Z; Wang X; Cheng H; Sun J; Yu H; Zhang G; Wu F; Liu J; Chen C
    Front Pharmacol; 2022; 13():1044798. PubMed ID: 36712662
    [No Abstract]   [Full Text] [Related]  

  • 34. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.
    Safdar A; Butt MH; Ahmad A; Zaman M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1195-1204. PubMed ID: 34096401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars.
    Uifălean A; Ilieş M; Nicoară R; Rus LM; Hegheş SC; Iuga CA
    Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30257528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolution of biosimilars in oncology, with a focus on trastuzumab.
    Nixon NA; Hannouf MB; Verma S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
    Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
    Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars.
    Azuz S; Newton M; Bartels D; Poulsen BK
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1495-1501. PubMed ID: 34008071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.